Stock vs Stock Comparison

ResMed Inc. vs Eli Lilly and Company

RMD and LLY are evenly matched across key metrics.

RMD$182.82
LLY$1064.15

🏆 Tale of the Tape

44
RMDLLY
27.2%Profitability (Net Margin)31.7%
18.4xValuation (P/E)39.2x
18.6%Efficiency (ROIC)30.4%
7/9Health (Piotroski F)7/9
11.8Safety (Altman Z)7.8
9.8%Growth (Rev YoY)44.7%
0.21Risk (Sharpe 1Y)0.61
0.37xBalance Sheet (D/E)3.24x
5.02%FCF Yield0.68%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.231
252-Day Correlation
0.228
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricRMDLLY
Market Cap$27.6B$985.4B
P/E Ratio18.4x39.2x
Forward P/E15.6x24.8x
P/B4.26x31.65x
Dividend Yield1.26%0.63%
Beta0.840.48

Quantitative Metrics

MetricRMDLLY
DCF Fair Value$289.83$296.11
DCF Upside+25.9%-68.2%
Piotroski F7/97/9
Altman Z11.807.84
Beneish M-2.62-1.91
FCF Yield5.02%0.68%
Net Debt/EBITDA-0.3x1.1x
ROIC18.6%30.4%
WACC10.4%7.8%
ROIC – WACC8.2pp22.5pp
Gross Margin59.4%83.0%
Net Margin27.2%31.7%
Rev Growth YoY9.8%44.7%
Sharpe (1Y)0.210.61
Max Drawdown 3Y
FCF Payout Ratio19%90%

RMD Price

Loading chart...

LLY Price

Loading chart...

ETF Exposure

RMD found in:

IHI4.52%
XHE1.49%
VOT0.73%
XLV0.57%
VHT0.51%
VO0.32%
ONEV0.21%
RSP0.20%
ONEO0.16%
SCHG0.14%
VIG0.14%
VUG0.10%
IWD0.08%
QUS0.07%
VONV0.07%
ESGV0.07%
SPLG0.06%
SCHX0.06%
IVV0.06%
SCHB0.06%
ITOT0.05%
VONE0.05%
VOO0.05%
SPYG0.05%
SPY0.05%
SPYV0.05%
SPTM0.05%
URTH0.04%
VTI0.04%
ACWI0.04%
DGRW0.04%
IWF0.03%
VONG0.02%

LLY found in:

XLV15.40%
IYH13.72%
VHT12.15%
VIG3.33%
SCHG3.17%
QUAL2.92%
MGK2.82%
IWF2.66%
VONG2.42%
SPYG2.36%
VUG2.31%
IVW2.23%
QUS1.95%
XPH1.90%
ESGV1.48%
DGRW1.46%
IVV1.46%
SCHX1.34%
SPY1.29%
ITOT1.29%
SCHB1.25%
VFQY1.23%
VOO1.20%
SPTM1.20%
VTI1.14%
VONE1.14%
SPLG1.10%
ARKG1.04%
URTH0.99%
ACWI0.87%
VT0.66%
VFMO0.46%
RSP0.20%
ONEO0.02%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

RMD vs LLY: Head-to-Head Analysis

ResMed Inc. (RMD) and Eli Lilly and Company (LLY) represent two companies in the Healthcare sector. Our quantitative Tale of the Tape shows these companies are evenly matched across profitability, valuation, and risk metrics.

In terms of capital efficiency, RMD generates a return on invested capital (ROIC) of 18.6% compared to LLY's 30.4%. This suggests LLY is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between RMD and LLY is 0.231, indicating low correlation, making them an effective diversification pair in a portfolio context.

RMD appears in 33 ETFs tracked by SecuritiesDB, while LLY appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, RMD or LLY?

Our quantitative analysis compares RMD and LLY across nine fundamental dimensions. RMD and LLY are evenly matched across key metrics. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are RMD and LLY correlated?

The 252-day correlation between RMD and LLY is 0.231. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.